Dr. Explains Why Retatrutide is KING of Fat Loss Peptides
A doctor-creator's 11-minute explainer on how retatrutide differs from semaglutide and tirzepatide, with her views on muscle loss, side effects, dosing and availability.
With Dr. Ashley Froese
Key moments
Tap a moment to play the video from there.
- 0:00Questions the video promises to answerFroese lists common questions about retatrutide, such as switching from tirzepatide and muscle loss. She says she is a doctor on the internet, not the viewer's doctor.
- 0:20Good, better, best GLP-1 blendsShe says the newer blends add a metabolism boost to appetite and insulin resistance effects. She claims retatrutide raises metabolic rate while losing fat in a deficit.
- 1:04Semaglutide, tirzepatide and GIPFroese contrasts pure GLP-1 agonism with the GLP-1 plus GIP combination. She credits GIP with fewer side effects, more weight loss and a temporary rise in energy expenditure.
- 3:35What glucagon adds in retatrutideShe describes glucagon as a fat vacuum that, alongside GLP-1 and GIP, is diverted toward fat burning and heat production through mitochondrial uncoupling.
- 5:07Avoiding metabolic adaptationShe argues the glucagon signal prevents the slowed metabolism that usually stalls weight loss. She adds that it cannot replace exercise.
- 5:57Muscle loss and protein adviceFroese says up to 40% of weight lost in trials can be lean mass. She recommends at least 1 g of protein per pound of lean body mass and tracking muscle.
- 7:05Sponsored muscle tracking scaleShe promotes a Hum Health Body Pod scale, saying its readings matched her DEXA scan. This segment is sponsored.
- 7:48Heart rate, skin and gallbladder risksShe lists higher resting heart rate, sunburn-like skin sensitivity at 12 mg, pancreatitis under 0.5% in trials, and gallstones with rapid weight loss.
- 9:01Trial dosing and microdosing theoryFroese gives the trial dose steps and 4-week intervals. She shares her own unproven theory that microdosing might speed up tolerance.
- 10:31Why it is not yet availableShe says retatrutide is still in clinical trials and will be approved for human use at an unknown date, though people use research-purpose products now.
What the video says
In this 11-minute video, Dr. Ashley Froese compares retatrutide with semaglutide and tirzepatide. She frames them as good, better and best versions of weight loss peptide blends, and says at the start that the video is not medical advice. A segment in the middle is sponsored by Hum Health.
Froese describes semaglutide as pure GLP-1 receptor agonism that lowers appetite and slows digestion, with nausea and constipation as the trade-off. She says tirzepatide adds GIP, which she credits with fewer side effects, easier fat mobilization and a temporary rise in energy expenditure through what she calls a futile calcium cycle. She cites average weight loss in studies rising from 15% on GLP-1 alone to 20 to 25% on tirzepatide. Retatrutide, she says, adds glucagon receptor agonism, which she describes as driving fat burning and heat production through mitochondrial uncoupling. She argues this prevents the metabolic adaptation that usually stalls weight loss.
The second half covers what she calls the catches. She says up to 40% of weight lost on these blends in clinical trials can be lean mass, and she advises at least 1 g of protein per pound of lean body mass and tracking muscle. The sponsored segment promotes a Hum Body Pod home scale, which she says matched her DEXA scan. She then lists a resting heart rate increase of 5 to 10 beats per minute, skin sensitivity like sunburn reported by about 20% of participants at 12 mg, pancreatitis in under 0.5% of trial participants, and gallstones linked to rapid weight loss.
On dosing, she reports trial steps of 2, 4, 6, 9 and 12 mg at 4-week intervals. She offers a theory, which she labels as unproven, that microdosing could speed up receptor tolerance. She says retatrutide is still in clinical trials, that she expects approval at an unknown date, and that people are using research-purpose products in the meantime.
On each compound
Retatrutide3:35
Froese says retatrutide leans on GIP and adds glucagon receptor agonism. She claims this raises fat burning and resting energy expenditure and prevents metabolic adaptation, and she reviews side effects and trial doses of 2 to 12 mg.
See how your DNA reads RetatrutideTirzepatide1:04
Froese describes tirzepatide as GLP-1 plus GIP agonism. She says it brings fewer side effects and 20 to 25% weight loss in studies, plus a temporary rise in energy expenditure.
See how your DNA reads TirzepatideSemaglutide1:04
Froese describes semaglutide as pure GLP-1 receptor agonism that reduces hunger and slows digestion. She says it comes with nausea and constipation.
See how your DNA reads Semaglutide“But safe doesn't mean side effect free.”
What this video doesn’t settle
- Froese cites trial figures without naming studies, so the weight loss, lean mass and side effect numbers cannot be checked from the video.
- Her claim that retatrutide prevents metabolic adaptation is stated as fact, with no data shown on metabolic rate over time.
- Her microdosing and receptor desensitization idea is, in her words, only a theory, and no evidence is offered.
Questions this video answers
How is retatrutide different from tirzepatide?
Froese says tirzepatide combines GLP-1 and GIP agonism, while retatrutide keeps a heavy GIP component and adds glucagon receptor agonism. She claims the glucagon part raises fat burning and heat production and prevents metabolic adaptation.
Does retatrutide cause muscle loss?
Froese says clinical trials show up to 40% of weight lost on these GLP agonist blends can be lean mass. She recommends at least 1 g of protein per pound of lean body mass and tracking muscle.
What side effects of retatrutide does Dr. Froese mention?
She mentions a resting heart rate increase of 5 to 10 beats per minute and sunburn-like skin sensitivity in about 20% of participants at 12 mg. She also mentions pancreatitis in under 0.5% of trial participants and gallstones with rapid weight loss.
What retatrutide doses were used in the trials according to this video?
Froese says the trial doses were 2 mg, 4 mg, 6 mg, 9 mg and 12 mg, each held for 4 weeks before increasing. She suggests this may become the recommended schedule.
Is retatrutide approved for human use?
Froese says it is still in clinical trials and not approved. She expects approval but says the timing is unknown.
Video by This Is Not Covered - Dr. Ashley Froese on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
